Renaissance Technologies LLC Decreases Stock Holdings in Cardiff Oncology, Inc. (NASDAQ:CRDF)

Renaissance Technologies LLC reduced its position in shares of Cardiff Oncology, Inc. (NASDAQ:CRDF - Free Report) by 19.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 483,090 shares of the company's stock after selling 119,294 shares during the period. Renaissance Technologies LLC owned approximately 0.94% of Cardiff Oncology worth $2,097,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. Raymond James Financial Inc. acquired a new position in Cardiff Oncology in the 4th quarter valued at approximately $56,000. Intech Investment Management LLC bought a new position in shares of Cardiff Oncology during the 4th quarter worth approximately $79,000. Thoroughbred Financial Services LLC raised its position in Cardiff Oncology by 43.8% in the 4th quarter. Thoroughbred Financial Services LLC now owns 19,614 shares of the company's stock valued at $85,000 after purchasing an additional 5,970 shares during the last quarter. Glenview Trust co acquired a new stake in shares of Cardiff Oncology in the 4th quarter valued at $104,000. Finally, HB Wealth Management LLC bought a new stake in Cardiff Oncology in the fourth quarter valued at about $105,000. 16.29% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright lifted their target price on Cardiff Oncology from $13.00 to $17.00 and gave the company a "buy" rating in a research report on Friday, February 28th.

Cardiff Oncology Stock Performance

Shares of NASDAQ CRDF traded up $0.02 during midday trading on Thursday, hitting $2.76. 90,875 shares of the stock traded hands, compared to its average volume of 1,123,300. The company has a market cap of $183.54 million, a PE ratio of -2.93 and a beta of 1.74. Cardiff Oncology, Inc. has a one year low of $2.01 and a one year high of $5.64. The business has a 50 day moving average price of $3.35 and a two-hundred day moving average price of $3.47.

Cardiff Oncology Profile

Cardiff Oncology, Inc, a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.